BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36898258)

  • 1. Real de-escalation or escalation in disguise?
    Banys-Paluchowski M; Rubio IT; Ditsch N; Krug D; Gentilini OD; Kühn T
    Breast; 2023 Jun; 69():249-257. PubMed ID: 36898258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary treatment for operable primary breast cancer.
    Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De-escalation of axillary surgery in early breast cancer.
    Jatoi I; Benson JR; Toi M
    Lancet Oncol; 2016 Oct; 17(10):e430-e441. PubMed ID: 27733269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
    Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
    Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-escalation of axillary irradiation for early breast cancer - Has the time come?
    Senkus E; Cardoso MJ; Kaidar-Person O; Łacko A; Meattini I; Poortmans P
    Cancer Treat Rev; 2021 Dec; 101():102297. PubMed ID: 34656018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical management of early stage invasive breast cancer: a practice guideline.
    McCready D; Holloway C; Shelley W; Down N; Robinson P; Sinclair S; Mirsky D; ;
    Can J Surg; 2005 Jun; 48(3):185-94. PubMed ID: 16013621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast surgery after neoadjuvant therapy.
    Gnant M
    Curr Opin Oncol; 2022 Nov; 34(6):643-646. PubMed ID: 36083127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
    Kuemmel S; Heil J; Rueland A; Seiberling C; Harrach H; Schindowski D; Lubitz J; Hellerhoff K; Ankel C; Graßhoff ST; Deuschle P; Hanf V; Belke K; Dall P; Dorn J; Kaltenecker G; Kuehn T; Beckmann U; Potenberg J; Blohmer JU; Kostara A; Breit E; Holtschmidt J; Traut E; Reinisch M
    Ann Surg; 2022 Nov; 276(5):e553-e562. PubMed ID: 33156057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary surgery in breast cancer: the beginning of the end.
    Dumitru D; Khan A; Catanuto G; Rocco N; Nava MB; Benson JR
    Minerva Chir; 2018 Jun; 73(3):314-321. PubMed ID: 29589679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
    Wazir U; Mokbel K
    Anticancer Res; 2020 Oct; 40(10):5351-5354. PubMed ID: 32988853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
    Jung JG; Ahn SH; Lee S; Kim EK; Ryu JM; Park S; Lim W; Jung YS; Chung IY; Jeong J; Chang JH; Shin KH; Chang JM; Moon WK; Han W
    BMC Cancer; 2022 Feb; 22(1):189. PubMed ID: 35184724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Accuracy of Sentinel Lymph Node Biopsy Alone in Clinically Node-Positive Patients Undergoing Upfront Surgery for Invasive Breast Cancer: A Systematic Review.
    Lovrics O; Tao B; Parvez E
    Curr Oncol; 2023 Mar; 30(3):3102-3110. PubMed ID: 36975448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat sentinel lymph node biopsy in patients with ipsilateral recurrent breast cancer after breast-conserving therapy and negative sentinel lymph node biopsy: a prospective study.
    Folli S; Falco G; Mingozzi M; Buggi F; Curcio A; Ferrari G; Taffurelli M; Regolo L; Nanni O
    Minerva Chir; 2016 Apr; 71(2):73-9. PubMed ID: 26207566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
    Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
    Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Che Bakri NA; Kwasnicki RM; Khan N; Ghandour O; Lee A; Grant Y; Dawidziuk A; Darzi A; Ashrafian H; Leff DR
    Ann Surg; 2023 Apr; 277(4):572-580. PubMed ID: 35946806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
    Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
    Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
    Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.